Home News Page 61

News

Seattle Genetics Highlights Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2013

Seattle Genetics today summarized Adcetris®(brentuximab vedotin) data in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma from multiple presentations at the...

ImmunoGen Initiates Phase I Testing of Its EGFR-Targeting ADC, IMGN289

ImmunoGen said that it started clinical testing with its EGFR-targeting ADC, IMGN289, a novel Antibody-drug Conjugate (ADC). The trial...

ImmunoGen Discontinues IMGN901 Study in Small-Cell Lung Cancer (SCLC)

ImmunoGen has stopped the IMGN901 Phase II SCLC study. The decision is based on the recommendation of the trial's...

ADC Therapeutics adds an Additional Proprietary ADC Development Program in Oncology – Licenses Proprietary...

ADC Therapeutics specialized in the development of proprietary antibody drug conjugates and Five Prime Therapeutics, a clinical-stage biotechnology company...

Phase I Trial of Seattle Genetics’ SGN-LIV1A for Patients with LIV-1-Positive Metastatic Breast Cancer...

A new phase 1 clinical trial evaluating SGN-LIV1A for patients with LIV-1-positive metastatic breast cancer has started. SGN-LIV1A utilizes...

MedImmune, AstraZeneca’s Global Biologics Research and Development Arm, Acquires Spirogen and Enteres into a...

AstraZeneca global biologics research and development arm MedImmune, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate...

SAFC Invests in Commercial-Scale ADC Conjugation Manufacturing and Services

SAFC® Commercial, Sigma-Aldrich Corporation's custom manufacturing services business unit, is expanding two of its manufacturing facilities in the United...

New [14C]-labelled ADCs Service Offered by Almac

In recent years the interest in antibody drug conjugates for the targeted treatment of various cancer types has grown...

Carbogen Amcis AG Makes Capital Investments in ADC – New ADC Capabilities Benefit Oncology...

Switzerland-based Carbogen Amcis announced a series of significant investments designed to enhancing its antibody drug conjugate (ADC) capabilities to...

BMS Partners Again with Ambrx, in Up-to-$112M-and-Up ADC Collaboration

Bristol-Myers Squibb (BMS) will use Ambrx’s protein medicinal technology to develop antibody drug conjugates (ADCs) for unspecified cancer indications,...

FEATURED RESOURCES